Akorn Inc v.

Court of Appeals for the Third Circuit·Decided November 25, 2022·No. 21-2973·Unpublished

Opinion

NOT PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT

No. 21-2973

IN RE: AKORN INC.

AFSCME DISTRICT COUNCIL 47 HEALTH & WELFARE FUND; SERGEANTS BENEVOLENT ASSOCIATION HEALTH AND WELFARE FUND, Appellants

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE (D.C. No. 1-20-cv-01254)

District Judge: Honorable Maryellen Noreika

Submitted Under Third Circuit L.A.R. 34.1(a)

September 20, 2022

Before: AMBRO, RESTREPO, and FUENTES, Circuit Judges.

(Filed: November 25, 2022)

OPINION*

*

This disposition is not an opinion of the full Court and, pursuant to I.O.P. 5.7, does not constitute binding precedent.

RESTREPO, Circuit Judge.

This appeal concerns a challenge to the approval of a Chapter 11 bankruptcy plan (the “Plan”). Appellants are unsecured creditors of Appellee, Akorn, Inc. They raise several defects in the Plan that they claim left insufficient value to afford their creditor class a recovery under its waterfall. The Bankruptcy Court approved the Plan and the District Court affirmed. We will likewise affirm.

I.

We presume the parties’ familiarity with the case and set out only the facts needed for the discussion below.

The Parties. Appellee Akorn is a pharmaceutical company in the business of generic and branded health products. Appellants are among plaintiffs to a multidistrict litigation against Akorn and other generic drug manufacturers for alleged anti- competitive conduct. In re Generic Pharms. Pricing Antitrust Litig., No. 2:16-MD-2724- CMR (E.D. Pa. Aug. 5, 2016).

The Merger and Related Pre-Petition Settlement. After a failed merger with Fresenius Kabi AG in April 2018, Akorn settled related securities litigation with a class of shareholders in August 2019. In re Akorn, Inc. Data Integrity Secs. Litig., No. 1:18- CV-1713 (N.D. Ill. Mar. 8, 2018) (the “Class Action Settlement”). Settling plaintiffs, excluding those who opted out (the “Opt-Out Shareholders”), received a distribution of

$27.5 million directly from a D&O insurance carrier and approximately 6.7 million shares of Akorn common stock.

The Sale. The failed merger and Akorn’s associated financial issues subsequently affected a loan agreement with Akorn’s secured lenders (the “Secured Lenders”), and a Standstill Agreement was later reached between the two, allowing Akorn some “breathing room” to either refinance or pay down its debts. JA385.

The Secured Lenders eventually agreed to serve as a stalking-horse bidder in Chapter 11, preserving Akorn’s business as a going concern through a “credit bid” on Akorn’s outstanding debt. JA130. The Secured Lenders subsequently agreed to purchase the bulk of Akorn’s assets in exchange for a release of Akorn’s debt under the loan agreement. The Secured Lenders also agreed to assume $5 million of Akorn’s additional undisputed non-litigation unsecured debt.

Not included in the sale were a remaining D&O insurance policy, hypothetical avoidance actions to recover the Class Action Settlement, liabilities arising from litigation against Akorn by Provepharm, and a 50% interest in a defunct nasal spray product (together, the “Retained Assets”). The Bankruptcy Court approved the sale over Appellants’ objections, noting that “the market has spoken with respect to the value of the debtor’s assets,” as “[t]he current offer is the best and only actionable transaction supported by most parties in interest.” JA589.

The Chapter 11 Plan. Akorn’s reorganization plan included eight classes, with the Secured Lenders in “Class 3,” and unsecured claimants, like Appellants, in “Class 4.” Class 3 was designated an “impaired” class, and as such, its approval of the Plan allowed

it to proceed, despite objections, as a Bankruptcy Code § 1129(b) “cramdown.” After a three-day trial, the Bankruptcy Court overruled Appellants’ objections and confirmed the Plan.

Disposal of the Retained Assets. Each of the remaining Retained Assets was then strategically disposed of as part of the wind-down process. Post-petition, Akorn settled with the Opt-Out Shareholders using funds from its remaining D&O insurance policy, but declined to avoid the Class Action Settlement, citing the cost and uncertainty of unwinding it. Akorn settled litigation with Provepharm, releasing its counterclaims to garner Provepharm’s support for the Plan. Similarly, Akorn settled litigation with Rising, its co-owner in the nasal spray product, in exchange for the rest of its share in the product and Rising’s support for the Plan.

II.

Appellants raised fifteen errors related to the Plan below; the District Court rejected all of them. On appeal, Plaintiffs assert that (1) the Retained Assets had value, and as such, the manner of their distribution under the Plan did not maximize the value of the estate and violated the absolute priority rule; (2) Akorn should have proceeded through Chapter 7 instead of Chapter 11; (3) the Plan misclassified creditors and treated certain classes unfairly; and (4) the Plan was put forth in bad faith.

III.

The District Court had jurisdiction pursuant to 28 U.S.C. § 158(a)(1). We have jurisdiction pursuant to 28 U.S.C. § 1291.

“Because the District Court sat as an appellate court to review the Bankruptcy Court, we review the Bankruptcy Court’s legal determinations de novo, its factual findings for clear error, and its exercises of discretion for abuse thereof.” In re Goody's Family Clothing Inc., 610 F.3d 812, 816 (3d Cir. 2010).1 IV.

We review each of Appellants’ challenges to the Plan in turn.

A. Improper Designation of Retained Assets as Having No Value Frustrated that they did not recover on their unsecured litigation claims against Akorn under the Plan, Appellants argue that Akorn’s distribution of the Retained Assets violated the absolute priority rule and constituted a failure to maximize the value of the estate available to creditors like themselves.

The absolute priority rule bars transfers of property under a plan to creditors junior to a claimant class (here an unsecured class), absent the senior class’s consent. 11 U.S.C. § 1129(b)(2)(B)(ii). Appellants argue that the Retained Assets were valuable estate property that should have been used to satisfy their claims and not distributed to junior creditors. The Bankruptcy Court implicitly and the District Court explicitly rejected this

1 More specifically, the Bankruptcy Court’s findings as to the value of estate property are reviewable for clear error. See In re Fruehauf Trailer Corp., 444 F.3d 203, 214 (3d Cir. 2006). A bankruptcy court’s factual finding “that creditors rejecting the plan would not receive a greater recovery in a Chapter 7 liquidation,” is reviewed for clear error. In re PWS Holding Corp., 228 F.3d, 224, 250 (3d Cir. 2000). Further, this Court “will uphold a plan’s classification scheme so long as it is reasonable and does not arbitrarily designate classes.” In re W.R. Grace & Co., 729 F.3d 311, 326 (3d Cir. 2013) (internal quotations omitted). Finally, we review the Bankruptcy Court’s good-faith determination for abuse of discretion. See In re SGL Carbon Corp., 200 F.3d 154, 159 (3d Cir. 1999).

Free access — add to your briefcase to read the full text and ask questions with AI

Akorn Inc v., (3d Cir. 2022).

Akorn Inc v. (Akorn Inc v.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related